Publications

5538 Results

Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: An intergroup study of the National Cancer Institute of Canada Clinical trials group and the Southwest Oncology Group.

Authors
N Murray;RB Livingston;FA Shepherd;K James;B Zee;A Langleben;M Kraut;J Bearden;JW Goodwin;C Grafton;A Turrisi;D Walde;H Croft;J Ottaway;D Gandara
Journal / Conference
Journal of Clinical Oncology 17(8):2300-2308
Year
1999
Research Committee(s)
Lung
Study Number(s)
SWOG-9216 (INT-0131) (NCIC-CTG-BR.8)

SWOG 95-01: A phase II trial of a combination of fludarabine and mitoxantrone (FN) in untreated advanced low grade lymphoma. An effective, well tolerated therapy.

Authors
W Velasquez;D Lew;T Miller;R Fisher
Journal / Conference
Proc of the American Society of Clinical Oncology 18:9a(#27)
Year
1999
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-9501

Carboplatin and paclitaxel (CARBO/TAX) for advanced transitional cell carcinoma (TCC) of the urothelium.

Authors
EJ Small;D Lew;DP Petrylak;ED Crawford
Journal / Conference
Proc of the American Society of Clinical Oncology 18:333a(#1280)
Year
1999
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-9457

Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-a for advanced renal cell carcinoma. A Southwest Oncology Group study.

Authors
L Elias;D Lew;RA Figlin;RC Flanigan;ME Thompson;PL Triozzi;RJ Belt;DP Wood;SE Rivkin;ED Crawford
Journal / Conference
Proc of the American Society of Clinical Oncology 18:331a(#1275)
Year
1999
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-9338

Preliminary toxicity results from Southwest Oncology Group trial (SWOG) 9705: A phase II trial of cisplatin, etoposide and paclitaxel (PET) with G-CSF in untreated patients (PTS) with extensive small cell lung cancer (SCLC).

Authors
PA Bunn;K Kelly;J Crowley;RB Livingston;DR Gandara
Journal / Conference
Proc of the American Society of Clinical Oncology 18:468a(#1807)
Year
1999
Research Committee(s)
Lung
Study Number(s)
S9705

A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial.

Authors
K Kelly;J Crowley;PA Bunn;RB Livingston;DR Gandara
Journal / Conference
Proc of the American Society of Clinical Oncology 18:461a(#1777)
Year
1999
Research Committee(s)
Lung
Study Number(s)
SWOG-9509

Preliminary analysis of the E1690/S9111/C9190 intergroup postoperative adjuvant trial of high-and low- dose IFNa2b (HDI and LDI) in high-risk primary or lymph node metastatic melanoma.

Authors
JM Kirkwood;J Ibrahim;V Sondak;M Ernstoff;L Flaherty;T Smith;J Richards;U Rao;M Steele;R Blum
Journal / Conference
Proc of the American Society of Clinical Oncology 18:537a(#2072)
Year
1999
Research Committee(s)
Melanoma
Study Number(s)
SWOG-9111 (EST-1690)

E2690: Intergroup immunological evaluation of IFNa2b dose-response in patients (Pts) with high-risk melanoma.

Authors
H Zarour;T Richards;T Whiteside;J Sosman;J Ibrahim;M Ernstoff;R Blum;JM Kirkwood
Journal / Conference
Proc of the American Society of Clinical Oncology 18:538a(#2079)
Year
1999
Research Committee(s)
Melanoma
Study Number(s)
SWOG-9325 (EST-2690)

Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101).

Authors
N Davison;A O'Neill;T Habermann;CK Osborne;S Martino;D White;MD Abeloff
Journal / Conference
Proc of the American Society of Clinical Oncology 18:67a(#249)
Year
1999
Research Committee(s)
Breast
Study Number(s)
SWOG-8851 (INT-0101) (EST-5188)

Concordance of pre-and post- chemotherapy p53 immunostaining, and its prognostic significance in epithelial ovarian cancer (EOC) receiving intraperitoneal (IP) consolidation: A Southwest Oncology Group study (SWOG-9521).

Authors
L Pandit;PY Liu;FM Muggia;JC Felix;D Hawes;KY Terada;JC Paradelo;RJ Cote;DS Alberts
Journal / Conference
Proc of the American Society of Clinical Oncology 18:382a(#1475)
Year
1999
Research Committee(s)
Gynecologic
Study Number(s)
SWOG-9521